Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 30, 2008

Conditions
Oral MucositisHead and Neck Cancer
Interventions
DRUG

Placebo

Placebo

DRUG

SCV-07

0.02 mg/kg

DRUG

SCV-07

0.10 mg/kg

Trial Locations (19)

10003

Beth Israel Medical Center, New York

10467

Montefiore Medical Center, The Bronx

18015

St Luke's Hospital & Health Network, Bethlehem

19140

Temple University, Philadelphia

19713

Helen F Graham Cancer Center, Newark

28203

Carolinas Medical Center, Charlotte

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

40202

James Graham Brown Cancer Center, Lousiville

43210

Ohio State University Medical Center, Columbis

48201

Karmanos Cancer Institute, Detroit

53226

Medical College of Wisconsin, Milwaukee

58501

Mid Dakota Clinic, Bismarck

60612

University of Illinois at Chicago, Chicago

63110

Washington University in St Louis, St Louis

68198

The Nebraska Medical Center, Omaha

72205

University of Arkansas for Medical Sciences, Little Rock

85013

Arizona Oncology Services Foundation, Phoenix

06856

Whittingham Cancer Center, Norwalk

Sponsors
All Listed Sponsors
lead

SciClone Pharmaceuticals

INDUSTRY